Science at Sanofi

The United in Rare: Advancing LSDs Care across Asia event was held on the 22^nd to 23^rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

The programme brought together international and local experts to discuss the evolving understanding of Type 2 inflammation in atopic dermatitis, with a focus on IL-4 and IL-13, disease modification, and the importance of early intervention across different patient populations. 

The United in Rare: Advancing LSDs Care across Asia event was held on the 22nd to 23rd November 2025 in Bangkok, Thailand. The event aimed to provide a platform for experts across Thailand, Malaysia, Singapore, Taiwan, South Korea and India to share their experiences in management of LSDs by discussing challenges cases and best practices to improve diagnosis and treatment pathways for LSDs.

Access the full recording of the webinar to gain insights on Atopic Dermatitis, Bullous Pemphigoid, and practical applications from leading experts.

Discover the latest breakthroughs in pediatric infectious diseases, focusing on Pertussis, Polio and Hib protection.

Watch now to gain useful update on the latest in COPD diagnosis and management.​

Chapter 2: Pompe High-Risk Screening in Asia

Chapter 3: Treatment Strategies for Pompe Disease

Chronic spontaneous urticaria (CSU) creates substantial patient burden through persistent wheals, angioedema, and debilitating itch that severely disrupts daily functioning. Emerging evidence positions type 2 inflammation as a driver of CSU pathogenesis. IL-4 plays a particularly crucial role by stimulating excessive IgE production and promoting formation of IgG anti-IgE autoantibodies—both pathways that trigger mast cell degranulation and subsequent CSU symptoms. This mechanistic understanding has opened therapeutic opportunities targeting type 2 inflammatory pathways for patients who remain symptomatic despite standard antihistamine therapy.​

Citation: Geba et al. Journal of Allergy and Clinical Immunology 2025;Vol.151: 756-766

Rare Disease Day raises awareness for the 300 million people worldwide living with a rare disease, along with their families and carers. Over 6,000 rare diseases are characterized by a wide range of conditions and symptoms that can vary not only between diseases but also among individuals with the same condition. Take the opportunity to support equitable access to diagnosis, treatment, healthcare, social support for those affected by rare diseases.

Nearly 1 in 3 patients with uncontrolled moderate‑to‑severe type 2 asthma achieved clinical remission with dupilumab. Our latest update highlights key QUEST/TRAVERSE data, remission criteria, and implications for practice.

LIBERTY AD CHRONOS was a randomized, double-blind, placebo-controlled trial in adults with 
moderate-to-severe atopic dermatitis

LIBERTY AD SOLO-CONTINUE was a randomized, double-blind, phase 3 clinical trial at 185 sites in North America, Europe, Asia, and Japan.